N-(4-hydroxyphenyl)-4-(4-nitrophenyl)-1,3-thiazole-2-amine | 941234-10-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-hydroxyphenyl)-4-(4-nitrophenyl)-1,3-thiazole-2-amine
• 英文别名: 4-(4-(4-nitrophenyl)thiazol-2-ylamino)phenol；4-{[4-(4-Nitrophenyl)-1,3-thiazol-2-yl]amino}phenol；4-[[4-(4-nitrophenyl)-1,3-thiazol-2-yl]amino]phenol
• CAS: 941234-10-2
• 化学式: C₁₅H₁₁N₃O₃S
• 分子量: 313.337
• InChiKey: PXYPXTOUOYAWOU-UHFFFAOYSA-N

物化性质

• 沸点：
  554.0±60.0 °C(predicted)
• 密度：
  1.465±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(4-hydroxyphenyl)-4-(4-nitrophenyl)-1,3-thiazole-2-amine 在 ferrous(II) sulfate heptahydrate 、 ammonium hydroxide 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以69%的产率得到4-(4-(4-aminophenyl)thiazol-2-ylamino)phenol
  参考文献：
  名称：

  Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism

  摘要：

  Eicosanoids like leukotrienes and prostaglandins play a considerable role in inflammation. Produced within the arachidonic acid (AA) cascade, these lipid mediators are involved in the pathogenesis of pain as well as acute and chronic inflammatory diseases like rheumatoid arthritis and asthma. With regard to the lipid cross-talk within the AA pathway, a promising approach for an effective anti-inflammatory therapy is the development of inhibitors targeting more than one enzyme of this cascade. Within this study, thirty N-4-diaryl-1,3-thiazole-2-amine based compounds with different substitution patterns were synthesized and tested in various cell-based assays to investigate their activity and selectivity profile concerning five key enzymes involved in eicosanoid metabolism (5-, 12-, 15-lipoxygenase (LO), cyclooxygenase-1 and -2 (COX-1/-2)). With compound 7, 2-(4-phenyl)thiazol-2-ylamino)phenol (ST-1355), a multi-target ligand targeting all tested enzymes is presented, whereas compound 9, 2-(4-(4-chlorophenyl)thiazol-2-ylamino)phenol (ST-1705), represents a potent and selective 5-LO and COX-2 inhibitor with an IC50 value of 0.9 ± 0.2 μM (5-LO) and a residual activity of 9.1 ± 1.1% at 10 μM (COX-2 product formation). The promising characteristics and the additional non-cytotoxic profile of both compounds reveal new lead structures for the treatment of eicosanoid-mediated diseases.

  DOI：

  10.1016/j.ejmech.2014.07.025
• 作为产物：
  描述：

  N-苯甲酰基-N'-(4-羟基苯基)硫脲 在 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 1.5h， 生成 N-(4-hydroxyphenyl)-4-(4-nitrophenyl)-1,3-thiazole-2-amine
  参考文献：
  名称：

  Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism

  摘要：

  Eicosanoids like leukotrienes and prostaglandins play a considerable role in inflammation. Produced within the arachidonic acid (AA) cascade, these lipid mediators are involved in the pathogenesis of pain as well as acute and chronic inflammatory diseases like rheumatoid arthritis and asthma. With regard to the lipid cross-talk within the AA pathway, a promising approach for an effective anti-inflammatory therapy is the development of inhibitors targeting more than one enzyme of this cascade. Within this study, thirty N-4-diaryl-1,3-thiazole-2-amine based compounds with different substitution patterns were synthesized and tested in various cell-based assays to investigate their activity and selectivity profile concerning five key enzymes involved in eicosanoid metabolism (5-, 12-, 15-lipoxygenase (LO), cyclooxygenase-1 and -2 (COX-1/-2)). With compound 7, 2-(4-phenyl)thiazol-2-ylamino)phenol (ST-1355), a multi-target ligand targeting all tested enzymes is presented, whereas compound 9, 2-(4-(4-chlorophenyl)thiazol-2-ylamino)phenol (ST-1705), represents a potent and selective 5-LO and COX-2 inhibitor with an IC50 value of 0.9 ± 0.2 μM (5-LO) and a residual activity of 9.1 ± 1.1% at 10 μM (COX-2 product formation). The promising characteristics and the additional non-cytotoxic profile of both compounds reveal new lead structures for the treatment of eicosanoid-mediated diseases.

  DOI：

  10.1016/j.ejmech.2014.07.025

文献信息

• Synthesis and Biological Evaluation of N-aryl-4-aryl-1,3-Thiazole-2-Amine Derivatives as Direct 5-Lipoxygenase Inhibitors
  作者：Jeehee Suh、Eul Kgun Yum、Hyae Gyeong Cheon、Young Sik Cho

  DOI：10.1111/j.1747-0285.2012.01371.x

  日期：2012.7

  Biological evaluation of N‐aryl‐4‐aryl‐1,3‐thiazole‐2‐amine derivatives was examined for anti‐inflammatory activity in in vitro and in vivo assays. The thiazole compounds showed direct inhibition of 5‐lipoxygenase (LOX) that is a key enzyme of leukotrienes synthesis and involved in the inflammation‐related diseases, including asthma and rheumatoid arthritis. To optimize biological activity, we synthesized 1

  在体外和体内试验中，对N-芳基-4-芳基-1,3-噻唑-2-胺衍生物进行了生物学评估，以评估其抗炎活性。噻唑化合物显示出对5-脂氧合酶（LOX）的直接抑制，这是白三烯合成的关键酶，并参与炎症相关疾病，包括哮喘和类风湿关节炎。为了优化生物活性，我们合成了1,3-噻唑-2-胺衍生物，并研究了结构和活性之间的关系。尤其是，N-（3,5-二甲基苯基）-4-（4-氯苯基）-1,3-噻唑-2-胺被证明具有有效的抗炎活性，可作为5-LOX抑制剂。
• Inhibitory Effect of 4-Aryl 2-Substituted Aniline-thiazole Analogs on Growth of Human Prostate Cancer LNCap Cells
  作者：Seung-Hwa Baek、Nak-Jeong Kim、Seong-Hwan Kim、Kwang-Hwa Park、Kyung-Chae Jeong、Bae-Keun Park、Nam-Sook Kang

  DOI：10.5012/bkcs.2012.33.1.111

  日期：2012.1.20

  Androgen receptor (AR) is ligand-inducible nuclear hormone receptor which has been focused on key molecular target in growth and progression of prostate cancer. We synthesized a series of 4-aryl 2-substituted aniline-thiazole analogs and evaluated their anti-cancer activity in AR-dependent human prostate cancer LNCap cells. Among them, the compound 6 inhibited the tumor growth in LNCap-inoculated xenograft model.

  雄激素受体（AR）是一种配体诱导的核激素受体，已成为前列腺癌生长和进展的关键分子靶点。我们合成了一系列4-芳基-2取代的苯胺-噻唑类似物，并评估了它们在AR依赖的人前列腺癌LNCap细胞中的抗癌活性。在这些化合物中，化合物6抑制了LNCap移植模型中的肿瘤生长。
• A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase
  作者：Sabrina Heng、Kimberly R. Gryncel、Evan R. Kantrowitz

  DOI：10.1016/j.bmc.2009.04.030

  日期：2009.6

  The identification of a proper lead compound for fructose 1,6-bisphosphatase (FBPase) is a critical step in the process of developing novel therapeutics against type-2 diabetes. Herein, we have successfully generated a library of allosteric inhibitors against FBPase as potential anti-diabetic drugs, of which, the lead compound 1b was identified through utilizing a virtual high-throughput screening (vHTS) system, which we have developed. The thiazole-based core structure was synthesized via the condensation of alpha-bromoketones with thioureas and substituents on the two aryl rings were varied. 4c was found to inhibit pig kidney FBPase approximately fivefold better than 1b. In addition, we have also identified 10b, a tight binding fragment, which can be use for fragment-based drug design purposes. (C) 2009 Elsevier Ltd. All rights reserved.
• Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism
  作者：Carmen B. Rödl、Dominik Vogt、Simon B.M. Kretschmer、Katja Ihlefeld、Sebastian Barzen、Astrid Brüggerhoff、Janosch Achenbach、Ewgenij Proschak、Dieter Steinhilber、Holger Stark、Bettina Hofmann

  DOI：10.1016/j.ejmech.2014.07.025

  日期：2014.9

  Eicosanoids like leukotrienes and prostaglandins play a considerable role in inflammation. Produced within the arachidonic acid (AA) cascade, these lipid mediators are involved in the pathogenesis of pain as well as acute and chronic inflammatory diseases like rheumatoid arthritis and asthma. With regard to the lipid cross-talk within the AA pathway, a promising approach for an effective anti-inflammatory therapy is the development of inhibitors targeting more than one enzyme of this cascade. Within this study, thirty N-4-diaryl-1,3-thiazole-2-amine based compounds with different substitution patterns were synthesized and tested in various cell-based assays to investigate their activity and selectivity profile concerning five key enzymes involved in eicosanoid metabolism (5-, 12-, 15-lipoxygenase (LO), cyclooxygenase-1 and -2 (COX-1/-2)). With compound 7, 2-(4-phenyl)thiazol-2-ylamino)phenol (ST-1355), a multi-target ligand targeting all tested enzymes is presented, whereas compound 9, 2-(4-(4-chlorophenyl)thiazol-2-ylamino)phenol (ST-1705), represents a potent and selective 5-LO and COX-2 inhibitor with an IC50 value of 0.9 ± 0.2 μM (5-LO) and a residual activity of 9.1 ± 1.1% at 10 μM (COX-2 product formation). The promising characteristics and the additional non-cytotoxic profile of both compounds reveal new lead structures for the treatment of eicosanoid-mediated diseases.